Instil Bio (5GT0) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
5GT0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Instil Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.20 |
| 52 Week High | US$11.03 |
| 52 Week Low | US$5.65 |
| Beta | 2.1 |
| 1 Month Change | 5.98% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GT0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.8% | 0.6% | 0.7% |
| 1Y | n/a | -18.1% | 7.3% |
Return vs Industry: Insufficient data to determine how 5GT0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 5GT0 performed against the German Market.
Price Volatility
| 5GT0 volatility | |
|---|---|
| 5GT0 Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 13.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 5GT0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5GT0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 14 | Bronson Crouch | instilbio.com |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer.
Instil Bio, Inc. Fundamentals Summary
| 5GT0 fundamental statistics | |
|---|---|
| Market cap | €43.92m |
| Earnings (TTM) | -€63.22m |
| Revenue (TTM) | n/a |
Is 5GT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GT0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$75.08m |
| Earnings | -US$75.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.07 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 70.3% |
How did 5GT0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 16:33 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Instil Bio, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |